Skip to main content

Cardiovascular Diseases Related to Diabetes and Obesity

112kviews
Editorial23 May 2022
Editorial: Cardiovascular Diseases Related to Diabetes and Obesity

Cardiovascular Diseases Related to Diabetes and Obesity

Worldwide, the prevalence of obesity continues to rise unabated due to the rapid urbanization in the developed and developing countries and poor lifestyle habits. Obesity is also attributed to the development of major cardiovascular diseases (CVD), diabetes, arthritis, behavioral changes, depression, cancers and hepatic diseases. Therefore, it is of paramount significance that the development of obesity is thwarted by introducing behavioral changes (aimed at decreasing the consumption of high calorie food and inculcating the habit of regular physical activity). Ironically, these interventions do not benefit the majority of people who are morbidly obese. Furthermore, it is pertinent to note that emerging knowledge from clinical studies indicates that available pharmacological modes of therapy may not be sufficient to reduce the development of adverse CVD events in patients who are obese and have co-morbidities such as diabetes, hypertension or hepatic diseases such as non-alcoholic steatosis, non-alcoholic steatohepatitis or alcoholic steatohepatitis. Therefore, the objective of this special issue is to compile the recent clinical and pre-clinical studies which could expand our horizon in understanding the etiopathogenesis of these intertwined, multifactorial diseases.

Comprehensive reviews have highlighted the epidemiological forecasting of diabetes. Cheng F et al., summarized that type 2 diabetes (T2DM) affected over 463 million people in 2019, and this number is expected to increase to 578 million by 2030 and 700 million by 2045; therefore, the priority objective is to identify all potential controllable risk factors for the development of diabetes with the purpose to have early screening and prevention [9]. Based on results from the China Health and Retirement Longitudinal Study, increased serum uric acid is an important risk factor for the development of diabetes, in postmenopausal women [9]. Venkatesan V et al. tried to determine the prevalence of T2DM and estimate its heritability using family-based cohorts from three distinct Endogamous Ethnic Groups, representing Northern and Southern states of India. The heritability estimates of T2DM in these regions ranged from 30% to 82%. Other T2DM related traits (e.g., BMI, lipids, blood pressure) in these regions exhibited strong additive genetic influences, suggesting the high burden of T2DM in Indian Endogamous Ethnic Groups with significant and differential additive genetic influences on T2DM and related traits [12].

An elegant review by Wu Y et al. highlights the critical role of mitochondria in the pathogenies of diabetes. Mitochondrial-derived peptides (MDPs) are recognized as short peptides formed by transcription and translation of the open reading frame site in human mitochondrial DNA. During stress the cell can use MDPs as a new type of reverse signal molecule to retrograde pass the signals to the nucleus where gene transcription synthesis is turned on to exert anti-inflammatory, anti-apoptotic signals and bolster the mitochondrial physiology, thereby mitigating the development of diabetes and CVD [3]. Studies have shown a difference in serum apelin levels between individuals with and without diabetic and/or obesity, supporting the role of apelin in diabetes and obesity development and also implying the potential use of apelin as a clinical biomarker for diabetes and obesity. Therefore, additional clinical and experimental studies clearly supporting the physiological and pathophysiological roles of the apelin–APJ system in glucose and lipid metabolism, particularly with its signaling pathways, is warranted [4].

In terms of diabetic complications, Chen S et al. analyzed patients with acute myocardial infarction (AMI), admitted into a coronary care unit with follow-up of ≥1 year based on two cohorts of MIMIC-III (Medical Information Mart for Intensive Care III) and CIN (Cardiorenal Improvement Registry) in the United States and China, and found that AMI patients with diabetes have a significantly higher 30-day mortality and increased 1-year mortality than AMI patients without diabetes [1]. Similarly, Du R et al., reported that insulin resistance is associated with increased risk of CVD development in adolescent subjects with diabetes [8]. Wu L et al. described that Apolipoprotein E polymorphisms are associated with the development of CVD in patients with or without T2DM [10]. Wu Y et al. also pointed out the critical role of mitochondria in the pathogenies of CVD in diabetes [3]. By utilizing bioinformatic analysis tools and validation with db/db T2DM mouse heart tissue, Huang X et al. revealed that calpain small subunit 1(CAPNS1) is highly expressed in the heart of T2DM db/db mice and this was significantly decreased in the heart of T2DM patients with SARS-CoV-2 infection, suggesting a novel target in mitigating the adverse effects of SARS-Cov-2 infection [2]. Although this is a novel and interesting hypothesis developed based on bioinformatic approach, the precise clinical significance is blurred and should be confirmed by additional preclinical and clinical studies.

Aberrant endothelial function in patients with T2DM is closely associated with the development of CVD. Flow-mediated dilation (FMD) is a noninvasive tool for evaluating endothelial function, which typically examines changes in the brachial artery diameter in response to ischemia using ultrasound Doppler. By evaluating FMD in patients with T2DM, Wang Y et al. performed a network meta-analysis to explore the improvement of endothelial function with antidiabetic drugs and found that glucagon-like peptide-1 receptor (GLP-1R) agonists, sodium glucose co-transporter-2 inhibitor and thiazolidinedione exhibited favorable effects in improving the endothelial function in T2DM patients [5]. Consistently, Dardano A et al. also reported the efficiency and safety of GLP-1R agonist in mitigating adverse effects of CVD in a T2DM patient living with HIV [11]. In addition, the pre-clinical study indicated the protective effects of GLP-1R agonists treatment in mitigating the development of diabetic cardiomyopathy [6]. Last, the meta-analysis by Sun Y et al revealed that sesamin dietary supplementation improved blood pressure and serum lipid profiles, and postulated sesamin as a supplement therapy or health supplement to prevent the development of CVDs [7].

In sum, the aforementioned articles published in this special issue highlight the multifaceted etiopathogenic aspects of closely connected diseases such as obesity and diabetes. It also sets the stage for delving further in deciphering the crucial link between obesity and diabetes. This could also help in unraveling the selective and specific biomarkers and or pharmacological targets, aiding in the management of these debilitating chronic diseases.

2,114 views

2 citations

ORIGINAL RESEARCH
14 April 2022
Burden of Type 2 Diabetes and Associated Cardiometabolic Traits and Their Heritability Estimates in Endogamous Ethnic Groups of India: Findings From the INDIGENIUS Consortium
Vettriselvi Venkatesan, 32 more and Solomon F. D. Paul

5,393 views

10 citations

ORIGINAL RESEARCH
18 March 2022
Role of Dapagliflozin and Liraglutide on Diabetes-Induced Cardiomyopathy in Rats: Implication of Oxidative Stress, Inflammation, and Apoptosis
Mohamed El-Shafey, 6 more and Nehal M. Elsherbiny

6,833 views

45 citations

The Role of Apelin–APJ System in Diabetes and Obesity
REVIEW
9 March 2022
The Role of Apelin–APJ System in Diabetes and Obesity
Cheng Li, 6 more and Yonggang Wang
Nowadays, diabetes and obesity are two main health threatening metabolic disorders in the world, which increase the risk for many chronic diseases. Apelin, a peptide hormone, exerts its effect by binding with angiotensin II protein J receptor (APJ), and is considered to be linked with diabetes and obesity. Apelin and its receptor are widely present in the body, and are involved in many physiological processes, such as glucose, and lipid metabolism, homeostasis, endocrine response to stress and angiogenesis. In this review, we summarize the literatures on the role of Apelin-APJ system in diabetes and obesity, for better understanding of the mechanism and function of apelin and its receptor in pathophysiology of diseases that may contribute to the development of new therapies.

18,127 views

122 citations

SYSTEMATIC REVIEW
17 March 2022
Effects of Antidiabetic Drugs on Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis
Yuhan Wang, 7 more and Zhaohui Lyu

5,537 views

18 citations

The Effects of Sesamin Supplementation on Obesity, Blood Pressure, and Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
SYSTEMATIC REVIEW
4 March 2022
The Effects of Sesamin Supplementation on Obesity, Blood Pressure, and Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Yiting Sun, 6 more and Yuxia Ma
Aims: Sesamin, the main lignin constituent of sesame, plays a pivotal role in regulating physical state. Some studies have evidenced that the supplementation of sesamin may decrease cardiovascular diseases risk. The goal of this systematic review was to summarize evidence of the effects of sesamin supplementation on obesity, blood pressure and lipid profile in humans by performing a meta-analysis of randomized controlled trials. Data Synthesis: Five databases (Pubmed, Cochrane Library, EMBASE, Web of Science and Scopus) were searched electronically from inception to July 30 2021 to identify randomized controlled trials that assessed the impact of sesamin on obesity, blood pressure and lipid profile. Weighted mean difference (WMD) and standard deviation (SD) were used to present the major outcomes. Conclusions: Seven trials (n= 212 participants) were included in the overall analysis. Results showed that sesamin supplementation causing greatly reductions in TC (WMD: -10.893, 95% CI: −19.745 to −2.041, p = 0.016), LDL-c (WMD: -8.429, 95% CI: −16.086 to −0.771, p = 0.031) and SBP (WMD: −3.662, 95% CI: −6.220 to −1.105, p = 0.005). Whereas it had no effect on HDL-c, TG, DBP, nor on weight. Subgroup analysis showed that duration, parallel-designed and unhealthy status can affect TC, LDL-c and SBP evidently. We didn’t discover a strong link between indicators included changes and duration of supplementation. Sesamin can be used as an obtainable dietary supplement to improve blood pressure and blood lipids, and further as a health product to prevent cardiovascular diseases.

12,946 views

30 citations

CASE REPORT
28 February 2022
Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report
Angela Dardano, 3 more and Stefano Del Prato

4,178 views

4 citations

REVIEW
3 February 2022
Mitochondrial-Derived Peptides in Diabetes and Its Complications
Ying Wu, 3 more and Delu Dong

9,800 views

35 citations

ORIGINAL RESEARCH
8 February 2022
Dissecting the Association of Apolipoprotein E Gene Polymorphisms With Type 2 Diabetes Mellitus and Coronary Artery Disease
Lei Wu, 5 more and Ting Xu

5,709 views

26 citations

ORIGINAL RESEARCH
14 December 2021
Does Diabetes Mellitus Increase the Short- and Long-Term Mortality in Patients With Critical Acute Myocardial Infarction? Results From American MIMIC-III and Chinese CIN Cohorts
Shiqun Chen, 15 more and Jiyan Chen

6,459 views

13 citations

ORIGINAL RESEARCH
28 January 2022
Mediating Effect of Body Mass Index and Dyslipidemia on the Relation of Uric Acid and Type 2 Diabetes: Results From China Health and Retirement Longitudinal Study
Fang Cheng, 3 more and Hongying Jia

3,997 views

13 citations